Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL280 Target Snapshot

Collagenase 3 · SINGLE PROTEIN · Homo sapiens

3,800Compounds
411Assays
2Approved Drugs
4,229.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Collagenase 3 shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P45452. Start with acne, then reuse UniProt P45452 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acne, then reuse UniProt P45452 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
acne

Collagenase 3 shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Collagenase 3 as ChEMBL target CHEMBL280, mapped to UniProt P45452. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Collagenase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL280
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P45452
Collagenase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Collagenase 3 is the right protein anchor across sources, using UniProt P45452 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acne is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCollagenase 3
UniProt AccessionP45452
Component TypeProtein
Sequence Length471 aa

Collagenase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Collagenase 3, mapped to UniProt P45452. Sequence length is 471 aa.

Mapped IDP45452
Review nameCollagenase 3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Collagenase 3 shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
acne
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
malaria
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
periodontitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
rosacea
2 linked drugs · 2 direct · 2 efficacy
Linked drugDOXYCYCLINE
Linked drugDOXYCYCLINE HYCLATE
Approved-linked Approved
anthrax infection
1 linked drug · 1 direct · 1 efficacy
Linked drugDOXYCYCLINE
Approved-linked Approved
bacterial disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDOXYCYCLINE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with acne because it currently carries approved-linked support. Linked drugs include DOXYCYCLINE, DOXYCYCLINE HYCLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacne
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
5
Phase III
9
Phase II
Assay Mix

Activity Type Distribution

IC503,677.0
KI551.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL440498 11.0 IC50 0.01 Clinical
CHEMBL3337892 10.82 IC50 0.015 Preclinical
CHEMBL317132 10.8 IC50 0.016 Preclinical
CHEMBL3337891 10.74 IC50 0.018 Preclinical
CHEMBL3337898 10.74 IC50 0.018 Preclinical
CHEMBL2064548 10.7 IC50 0.02 Preclinical
CHEMBL3337903 10.68 IC50 0.021 Preclinical
CHEMBL4087855 10.62 IC50 0.024 Preclinical
CHEMBL3337900 10.59 IC50 0.026 Preclinical
CHEMBL4094620 10.59 IC50 0.026 Preclinical
Distribution

pChEMBL Value Distribution

171
5.0
229
5.5
260
6.0
357
6.5
409
7.0
486
7.5
465
8.0
364
8.5
300
9.0
78
9.5
pChEMBL
Assay Landscape

Assay Landscape

411
Total Assays
2,871
Tested Compounds
4
Assay Types
Binding — 398 assays, 2,871 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 362 2,629 7.5
assay format 20 127 6.3
cell-based format 12 114 6.7
organism-based format 3 0
tissue-based format 1 1 7.5
ADME — 8 assays, 15 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 6 14 6.9
cell-based format 2 1 9.5
Functional — 3 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0
organism-based format 1 0
tissue-based format 1 1 7.9
Unassigned — 2 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 3 5.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine